Skip to main content
Top

14-06-2018 | Renal cell carcinoma | Article

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma

Journal: Nature Reviews Urology

Authors: Viktor Grünwald, Berit Eberhardt, Axel Bex, Anne Flörcken, Thomas Gauler, Thorsten Derlin, Martin Panzica, Hans Roland Dürr, Knut Achim Grötz, Rachel H. Giles, Christian von Falck, Anno Graser, Alexander Muacevic, Michael Staehler

Publisher: Nature Publishing Group UK

Abstract

Bone is a major site of haematogenous tumour cell spread in renal cell carcinoma (RCC), and most patients with RCC will develop painful and functionally disabling bone metastases at advanced disease stages. The prognosis of these patients is generally poor and the treatment is, therefore, aimed at palliation. However, RCC-associated bone metastases can be curable in select patients. Current data support a multimodal management strategy that includes wide resection of lesions, radiotherapy, systemic therapy, and other local treatment options, which can improve quality of life and survival. Nevertheless, the optimal approach for metastatic bone disease in RCC has not yet been defined and practical recommendations are rare. To improve the management and outcomes of patients with RCC and bone metastases, the International Kidney Cancer Coalition and the interdisciplinary working group on renal tumours of the German Cancer Society convened a meeting of experts with a global perspective to perform an unstructured review and elaborate on current treatment strategies on the basis of published data and expertise. The panel formulated recommendations for the diagnosis and treatment of patients with RCC and metastasis to the bone. Furthermore, the experts summarized current challenges and unmet patient needs that should be addressed in the future.
Literature
1.
Adiga, G. U. et al. Characterization of bone metastases in patients with renal cell cancer. BJU Int. 93, 1237–1240 (2004).PubMed
2.
Wood, S. L. & Brown, J. E. Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat. Rev. 38, 284–291 (2012).PubMed
3.
Woodward, E. et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48, 160–166 (2011).PubMed
4.
Weber, K., Doucet, M. & Kominsky, S. Renal cell carcinoma bone metastasis — elucidating the molecular targets. Cancer Metastasis Rev. 26, 691–704 (2007).PubMed
5.
Santoni, M. et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J. Exp. Clin. Cancer Res. 34, 10 (2015).PubMedPubMedCentral
6.
Zekri, J. et al. The skeletal metastatic complications of renal cell carcinoma. Int. J. Oncol. 19, 379–382 (2001).PubMed
7.
Patrick, D. L. et al. Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Support. Care Cancer 23, 1157–1168 (2015).PubMed
8.
Junker, K. et al. Genetic profile of bone metastases in renal cell carcinoma. Eur. Urol. 45, 320–324 (2004).PubMed
9.
Leitlinienprogramm Onkologie. S3 — Leitlinie, diagnostik, therapie und nachsorge des nierenzellkarzinom. AWMF http://​www.​awmf.​org/​uploads/​tx_​szleitlinien/​043-017OL-k_​S3_​Nierenzellkarzin​om_​2017-03.​pdf (2017).
10.
Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25 (Suppl. 3), iii49–56 (2014).PubMed
11.
Mottet, N. et al. EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer. EAU http://​uroweb.​org/​guideline/​prostate-cancer (2018).
12.
Motzer, R. et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 15, 804–834 (2017).PubMed
13.
Dabestani, S. et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 15, e549–561 (2014).PubMed
14.
Bianchi, M. et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann. Oncol. 23, 973–980 (2012).PubMed
15.
Santini, D. et al. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. PLOS One 8, e83026 (2013).PubMedPubMedCentral
16.
Aoki, J. et al. Osteoclast-mediated osteolysis in bone metastasis from renal cell carcinoma. Cancer 62, 98–104 (1988).PubMed
17.
Salapura, V. et al. Osteoblastic bone metastases from renal cell carcinoma. Radiol. Oncol. 48, 243–246 (2014).PubMedPubMedCentral
18.
Forbes, G. S., McLeod, R. A. & Hattery, R. R. Radiographic manifestations of bone metastases from renal carcinoma. AJR Am. J. Roentgenol. 129, 61–66 (1977).PubMed
19.
Yuasa, T. et al. Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin. Exp. Metastasis 28, 405–411 (2011).PubMed
20.
Toyoda, Y. et al. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur. Urol. 52, 163–168 (2007).PubMed
21.
Ivanyi, P. et al. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival? World J. Urol. 34, 909–915 (2016).PubMed
22.
Ruatta, F. et al. Prognosis of renal cell carcinoma with bone metastases: experience in 300 consecutive patients [abstract]. J. Clin. Oncol. 35, 463 (2017).
23.
Lin, P. P. et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J. Bone Joint Surg. Am. 89, 1794–1801 (2007).PubMed
24.
Fottner, A. et al. Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet. Disord. 11, 145 (2010).PubMedPubMedCentral
25.
Kume, H. et al. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? J. Urol. 185, 1611–1614 (2011).PubMed
26.
Chen, S. C. & Kuo, P. L. Bone metastasis from renal cell carcinoma. Int. J. Mol. Sci. 17, E987 (2016).PubMed
27.
Rybak, L. D. & Rosenthal, D. I. Radiological imaging for the diagnosis of bone metastases. Q. J. Nucl. Med. 45, 53–64 (2001).PubMed
28.
Sohaib, S. A. et al. Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br. J. Radiol. 82, 632–639 (2009).PubMed
29.
Gerety, E. L. et al. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Ann. Oncol. 26, 2113–2118 (2015).PubMedPubMedCentral
30.
Majhail, N. S. et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J. Clin. Oncol. 21, 3995–4000 (2003).PubMed
31.
Park, J. W., Jo, M. K. & Lee, H. M. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int. 103, 615–619 (2009).PubMed
32.
McDonald, J. S. et al. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology 267, 119–128 (2013).PubMed
33.
Shinoto, M. et al. Percutaneous osteoplasty for hypervascular bone metastasis. Radiat. Med. 26, 603–608 (2008).PubMed
34.
Leung, O. C. et al. Percutaneous cementoplasty of osteolytic metastases induces immediate and long-lasting pain relief in oncological patients. Hong Kong Med. J. 19, 317–322 (2013).PubMed
35.
Fuchs, B., Trousdale, R. T. & Rock, M. G. Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin. Orthop. Relat. Res. 431, 187–192 (2005).
36.
Kollender, Y. et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J. Urol. 164, 1505–1508 (2000).PubMed
37.
Alt, A. L. et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117, 2873–2882 (2011).PubMed
38.
Hwang, N. et al. Massive endoprosthetic replacement for bone metastases resulting from renal cell carcinoma: factors influencing patient survival. Eur. J. Surg. Oncol. 40, 429–434 (2014).PubMed
39.
Laufer, I. et al. Local disease control for spinal metastases following “separation surgery” and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J. Neurosurg. Spine 18, 207–214 (2013).PubMedPubMedCentral
40.
Patchell, R. A. et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366, 643–648 (2005).PubMed
41.
McDonald, R. et al. Effect of radiotherapy on painful bone metastases: a secondary analysis of the NCIC clinical trials group symptom control trial SC.23. JAMA Oncol. 3, 953–959 (2017).PubMedPubMedCentral
42.
Amini, A. et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract. Radiat. Oncol. 5, e589–e596 (2015).
43.
De Meerleer, G. et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 15, e170–e177 (2014).PubMed
44.
North, S. A. et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can. Urol. Assoc. J. 9, 164–170 (2015).PubMedPubMedCentral
45.
Taunk, N. K. et al. Spine radiosurgery in the management of renal cell carcinoma metastases. J. Natl Compr. Canc. Netw. 13, 801–809 (2015).PubMed
46.
Tree, A. C. et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 14, e28–e37 (2013).PubMed
47.
Wowra, B. et al. CyberKnife radiosurgery for malignant spinal tumors: characterization of well-suited patients. 33, 2929–2934 (2008).
48.
Mazeron, R. et al. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treat. Rev. 37, 476–486 (2011).PubMed
49.
De Wolf, K. et al. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiat. Oncol. 12, 157 (2017).PubMedPubMedCentral
50.
Wuthrick, E. J. et al. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer 117, 5548–5559 (2011).PubMedPubMedCentral
51.
Wersall, P. J. et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 77, 88–95 (2005).PubMed
52.
Chow, E. et al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol. 15, 164–171 (2014).PubMed
53.
Lee, J. et al. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer 104, 1894–1900 (2005).PubMed
54.
Zelefsky, M. J. et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 82, 1744–1748 (2012).PubMed
55.
Virk, M. S. et al. Frequency of symptomatic vertebral body compression fractures requiring intervention following single-fraction stereotactic radiosurgery for spinal metastases. Neurosurg. Focus 42, E8 (2017).PubMed
56.
Chow, E. et al. Palliative radiotherapy trials for bone metastases: a systematic review. J. Clin. Oncol. 25, 1423–1436 (2007).PubMed
57.
Rose, P. S. et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J. Clin. Oncol. 27, 5075–5079 (2009).PubMedPubMedCentral
58.
Cunha, M. V. et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int. J. Radiat. Oncol. Biol. Phys. 84, e343–e349 (2012).PubMed
59.
Sahgal, A. et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J. Clin. Oncol. 31, 3426–3431 (2013).PubMedPubMedCentral
60.
Thibault, I. et al. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. J. Neurosurg. Spine 21, 711–718 (2014).PubMed
61.
Sahgal, A. et al. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol. 14, e310–e320 (2013).PubMed
62.
Heron, D. E. et al. Single-session and multisession CyberKnife radiosurgery for spine metastases-University of Pittsburgh and Georgetown University experience. J. Neurosurg. Spine 17, 11–18 (2012).PubMed
63.
Mavrogenis, A. F. et al. Modern palliative treatments for metastatic bone disease: awareness of advantages, disadvantages, and guidance. Clin. J. Pain 32, 337–350 (2016).PubMed
64.
Gillams, A. Tumour ablation: current role in the liver, kidney, lung and bone. Cancer Imaging 8, S1–S5 (2008).PubMedPubMedCentral
65.
Lane, M. D. et al. Combination radiofrequency ablation and cementoplasty for palliative treatment of painful neoplastic bone metastasis: experience with 53 treated lesions in 36 patients. Skeletal Radiol. 40, 25–32 (2011).PubMed
66.
Pezeshki, P. S. et al. Comparison of the effect of two different bone-targeted radiofrequency ablation (RFA) systems alone and in combination with percutaneous vertebroplasty (PVP) on the biomechanical stability of the metastatic spine. Eur. Spine J. 25, 3990–3996 (2016).PubMed
67.
Ma, Y. et al. Percutaneous image-guided ablation in the treatment of osseous metastases from non-small cell lung cancer. Cardiovasc. Intervent. Radiol. 41, 726–733 (2018).PubMed
68.
Tanigawa, N. et al. Phase I/II study of radiofrequency ablation for painful bone metastases: Japan Interventional Radiology in Oncology Study Group 0208. Cardiovasc. Intervent. Radiol. 25, 267–266 (2018).
69.
Alemann, G. et al. Treatment of painful extraspinal bone metastases with percutaneous bipolar radiofrequency under local anesthesia: feasibility and efficacy in twenty-eight cases. J. Palliat. Med. 17, 947–952 (2014).
70.
Primavesi, F. et al. Thermographic real-time-monitoring of surgical radiofrequency and microwave ablation in a perfused porcine liver model. Oncol. Lett. 15, 2913–2920 (2018).PubMed
71.
Marcove, R. C. et al. Cryosurgery in the treatment of solitary or multiple bone metastases from renal cell carcinoma. J. Urol. 108, 540–547 (1972).PubMed
72.
Rohde, D. et al. Regional thermoablation of local or metastatic renal cell carcinoma. Oncol. Rep. 10, 753–757 (2003).PubMed
73.
Bang, H. J. et al. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J. Vasc. Interv. Radiol. 23, 770–777 (2012).PubMed
74.
Gardner, C. S. et al. Cryoablation of bone metastases from renal cell carcinoma for local tumor control. J. Bone Joint Surg. Am. 99, 1916–1926 (2017).PubMed
75.
Zugaro, L. et al. Treatment of osteolytic solitary painful osseous metastases with radiofrequency ablation or cryoablation: a retrospective study by propensity analysis. Oncol. Lett. 11, 1948–1954 (2016).PubMedPubMedCentral
76.
Zołnierek, J. et al. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J. Cancer Res. Clin. Oncol. 136, 371–378 (2010).PubMed
77.
Kalra, S. et al. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era. Clin. Genitourin. Cancer 15, 363–370 (2017).PubMed
78.
Maita, S. et al. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int. J. Cancer 130, 677–684 (2012).PubMed
79.
Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 17, 917–927 (2016).PubMed
80.
Fioramonti, M. et al. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. Oncotarget 8, 20113–20121 (2017).PubMedPubMedCentral
81.
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).PubMedPubMedCentral
82.
Saad, F. & Lipton, A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int. 96, 964–969 (2005).PubMed
83.
Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125–1132 (2011).PubMed
84.
Ripamonti, C. I. et al. Management of cancer pain: ESMO clinical practice guidelines. Ann. Oncol. 23 (Suppl. 7), vii139–154 (2012).PubMed
85.
Roelofs, A. J. et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr. Pharm. Des. 16, 2950–2960 (2010).PubMed
86.
Rosen, L. S. et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21, 3150–3157 (2003).PubMed
87.
Lipton, A. et al. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin. Cancer Res. 10, 6397S–403S (2004).PubMed
88.
Tunn, U. W. et al. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can. J. Urol. 19, 6261–6267 (2012).PubMed
89.
McKay, R. R. et al. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur. Urol. 66, 502–509 (2014).PubMedPubMedCentral
90.
Thompson, R. N. et al. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J. Bone Joint Surg. Br. 94, 385–390 (2012).PubMed
91.
Fusco, V. et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature. Clin. Genitourin. Cancer 13, 287–294 (2015).PubMed
92.
Henry, D. et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 22, 679–687 (2014).PubMed
93.
Lipton, A. et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur. J. Cancer 48, 3082–3092 (2012).PubMed
94.
Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. 23, 1341–1347 (2012).PubMed
95.
Khan, A. A. et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res. 30, 3–23 (2015).PubMed
96.
Kijima, T. et al. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int. 103, 620–624 (2009).PubMed
97.
Takeda, N. et al. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up. J. Orthop. Sci. 17, 770–774 (2012).PubMed
98.
Kijima, T. et al. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1. PLOS One 8, e64615 (2013).PubMedPubMedCentral
99.
Staehler, M. et al. Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int. 108, 673–678 (2011).PubMed
100.
Lutz, S. et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int. J. Radiat. Oncol. Biol. Phys. 79, 965–976 (2011).PubMed
101.
Fischer, M. & Kampen, W. U. Radionuclide therapy of bone metastases. Breast Care (Basel) 7, 100–107 (2012).
102.
Serafini, A. N. et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J. Clin. Oncol. 16, 1574–1581 (1998).PubMed
103.
Roque, I. F. M. et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst. Rev. 7, CD003347 (2011).
104.
Owen, R. J. Embolization of musculoskeletal bone tumors. Semin. Intervent. Radiol. 27, 111–123 (2010).PubMedPubMedCentral
105.
Forauer, A. R. et al. Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma. Acta Oncol. 46, 1012–1018 (2007).PubMed
106.
Pazionis, T. J. et al. Embolization of hypervascular bone metastases reduces intraoperative blood loss: a case-control study. Clin. Orthop. Relat. Res. 472, 3179–3187 (2014).PubMedPubMedCentral
107.
Pellerin, O. et al. Management of painful pelvic bone metastasis of renal cell carcinoma using embolization, radio-frequency ablation, and cementoplasty: a prospective evaluation of efficacy and safety. Cardiovasc. Intervent. Radiol. 37, 730–736 (2014).PubMed
108.
European Society for Medical Oncology. SOPs/instructions for authors and templates for standard ESMO clinical practice guidelines (CPGs) and ESMO-MCBS scores. ESMO https://​www.​esmo.​org/​content/​download/​77789/​1426712/​file/​ESMO-Clinical-Practice-Guidelines-Standard-Operating-Procedures.​pdf (2018).